Mylan N.V. has for the second time raised its offer to buy US-Irish-Israeli generic pharmaceuticals company Perrigo Company (NYSE:PRGO; TASE:PRGO). Mylan is now offering Perrigo shareholders $75 plus 2.3 Mylan shares per Perrigo share for a total of about $35.6 billion. RELATED ARTICLES "Mylan chairman is uncouth with an enormous ego" Can Mylan's poison pill thwart Teva takeover? Teva undeterred by Mylan rejection Perrigo falls after rejecting improved Mylan offer Perrigo rejects Mylan's $29b takeover bid The new offer reflects a share price of about $232.23 per Perrigo share based on prices on April 8 when Mylan made its first offer. The previous offer, which was rejected by Mylan, was for $222 per Perrigo share, comprising $60 in cash and 2.2 Mylan shares. Mylan itself is the subject of a $41 billion hostile takeover bid from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA). Mylan executive chairman Robert Coury dismissed Teva's offers as grossly undervaluing his company. Coury said today,""With this enhanced offer, I look forward to meeting with Joe Papa and his team to finalize the implementation of this truly compelling combination, which is a win-win for both Mylan and Perrigo shareholders and all other stakeholders."Published by Globes [online], Israel business news - www.globes-online.com - on April 29, 2015 © Copyright of Globes Publisher Itonut (1983) Ltd. 2015
